Product Description
Butalbital is a barbiturate that exerts its effect by mimicking the inhibitory effect of gamma-aminobutyric acid (GABA) by binding to a site, distinct from the benzodiazepine binding site, on the GABA receptor. This leads to an increase in the duration of GABA-mediated opening of chloridechannels and enhances the inhibitory effect of GABA. Consequently, its physiologic effects include sedation, hypnosis, reduction of anxiety, and respiratory depression and the drug causes tolerance and dependence. Butalbital is a member of the class of barbiturates that is barbituric acid in which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Butalbital)
Mechanisms of Action: GABA Antagonist,AMPA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Chile | New Zealand | Pakistan | Taiwan | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|